Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1Unknown 1Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Precancerous Conditions 6Uterine Cervical Neoplasms 3Uterine Cervical Dysplasia 2Malignant Neoplasms of Independent (Primary) Multiple Sites 2Small Cell Lung Carcinoma 1Recurrent respiratory papillomatosis 1Primary Condition: Advanced Tumors 1Papillomavirus Infections 1Neoplasms 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Malignant Neoplasms of Female Genital Organs 1Malignant Neoplasms of Digestive Organs 1Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic 1Malignant Neoplasm in the Head and Neck 1Lung Neoplasms 1Keratosis, Actinic 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Breast Cancer Female 1Advanced Malignant Neoplasm 1

Interventions

sapanisertib 1MLN 8237 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Malignant Neoplasms of Digestive Organs × Other neoplasm × Clear all
NCT02812056 2017-03-27

Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies

M.D. Anderson Cancer Center

Phase 1 Withdrawn
Other neoplasm

Malignant Neoplasms of Digestive Organs

Data powered by HemOnc (CC BY 4.0) Colophon âš¡